CLEVELAND – Sanford Markowitz, MD, PhD, a colon cancer researcher at the Ireland Cancer Center of University Hospitals Case Medical Center (UHCMC) has laid out the roadmap for how medical researchers should employ aspirin and aspirin-like drugs to prevent colon cancer in certain high-risk individuals.
In today’s New England Journal of Medicine, Dr. Markowitz’s editorial accompanies research by Dr. Charles Fuchs’ team at Harvard Medical School. The Harvard researchers discovered the hypothesized mechanism by which aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), called COX-2 inhibitors, act to decrease the risk of developing colon cancer.